Hydroxychloroquine enhances efferocytosis and modulates inflammation via MerTK/Gas6 signaling in a pristane-induced lupus mouse model.

This laboratory study investigated how hydroxychloroquine (HCQ), a common medication for autoimmune diseases like lupus, works at the cellular level. Researchers used mice with induced lupus-like disease to understand why HCQ helps reduce inflammation. They discovered that HCQ enhances a process called "efferocytosis," where immune cells called macrophages clean up dead and dying cells from the body. When this cleanup process doesn't work properly, it can contribute to autoimmune diseases. The study found that HCQ works by activating specific proteins (MerTK and Gas6) on macrophages, improving their ability to remove cellular debris and reducing inflammatory chemicals like IL-6 and interferon-alpha. Mice treated long-term with HCQ showed significantly reduced disease activity and kidney inflammation compared to untreated mice. The researchers confirmed these effects both in isolated cells and living animals, providing evidence for how HCQ produces its beneficial anti-inflammatory effects. This pharmaceutical research does not directly relate to acupuncture treatment. However, patients with lupus and other autoimmune conditions often use integrative approaches combining conventional medications with complementary therapies. If you're considering acupuncture as part of a comprehensive treatment plan for autoimmune disease, discuss this with your rheumatologist to ensure coordinated care. When seeking acupuncture treatment, always work with a licensed acupuncturist experienced in treating autoimmune conditions.

This preclinical study examined hydroxychloroquine's (HCQ) mechanism in a pristane-induced lupus (PIL) mouse model, focusing on efferocytosis enhancement. Researchers demonstrated that HCQ significantly upregulates MerTK/Gas6 signaling in macrophages, restoring efferocytotic capacity impaired in lupus. Long-term HCQ administration reduced inflammatory cytokines (IL-6, IFN-α), autoantibody titers, and lupus nephritis severity. In vitro studies using RAW264.7 cells and ex vivo peritoneal macrophages confirmed enhanced efferocytosis with HCQ treatment. MerTK inhibition via UNC2025 reversed HCQ's anti-inflammatory effects, confirming mechanism specificity. HCQ also increased anti-inflammatory markers including PPARγ, LXR, and IL-10. This pharmaceutical research clarifies HCQ's immunomodulatory mechanism through macrophage reprogramming rather than direct immunosuppression. Clinical takeaway: While this study elucidates conventional lupus therapy mechanisms, it doesn't directly inform acupuncture practice. Practitioners treating lupus patients on HCQ should maintain awareness of conventional treatment mechanisms when providing integrative care and coordinating with rheumatology colleagues.